SCHEMBL2283508

SCHEMBL2283508

OC(c1cccc(Br)c1)c1cccc(OC(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
DRD1 P21728 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
LMNA P02545 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
TAS2R14 Q9NYV8 1/20 0.37
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GRM4 Q14833 2/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14034026 0.85 TAS2R14 (0.46) MEP1BRAB9ADRD1KMT2AMEN1
SCHEMBL22904 0.82 DRD1 (0.46) MEP1BRAB9ANPC1DRD1KMT2A
SCHEMBL29539883 0.82 DRD1 (0.46) MEP1BRAB9ANPC1DRD1KMT2A
SCHEMBL31476387 0.80 IDO1 (0.47) IDO1TDO2SLC6A4
SCHEMBL241692 0.80 IDO1 (0.47) IDO1TDO2SLC6A4
SCHEMBL18529828 0.80 AOC3 (0.50) RAB9ANPC1MAPTLMNA
SCHEMBL31476413 0.80 AOC3 (0.50) RAB9ANPC1MAPTLMNA
SCHEMBL15943226 0.76 MEN1 (0.45) RAB9ANPC1DRD1KMT2AMEN1
SCHEMBL29699116 0.76 MEN1 (0.45) RAB9ANPC1DRD1KMT2AMEN1
SCHEMBL28045713 0.76 DRD1 (0.41) MEP1BRAB9ANPC1DRD1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245019-B1 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-11-14 EP disclosed
US-7989449-B2 4,5-dihydro-oxazol-2-yl amine derivatives HOFFMAN-LA ROCHE INC. (US) 2011-08-02 US disclosed
EP-2245019-A1 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-11-03 EP disclosed
WO-2009103626-A1 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 WO disclosed
US-20090209529-A1 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209529-A1 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES BACE2, BACE1, PSEN2 MEP1B 111/4885RAB9A 3788/4885NPC1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.